FRACTYL HEALTH INC. O.N. Aktie

Fractyl Health presented data at the H.C. Wainwright conference showing that the endoscopic Revita procedure substantially reduces weight regain after stopping GLP‑1 medications and has a favorable safety profile. The company expects pivotal top-line data in early Q4 2026 and plans a De Novo submission in late Q4 2026, with FDA feedback indicating a possible class II designation. Fractyl reports $47 million in cash, sees significant commercial potential, but remains dependent on approval, reimbursement and market acceptance. » Plus sur de.investing.com

H.C. Wainwright identifies Fractyl Health as a promising biotech opportunity and sees potential approval of the Revita treatment in 2027 with market launch in early 2028. The investment firm praises the commercial strategy of centers of excellence and existing infrastructure, which could enable a capital-efficient model and cash profitability within five to eight quarters after market entry. Analysts expect interim data from a 45‑patient cohort to support the design of a pivotal study of about 315 patients, as well as a possible de novo submission in Q4 2026. Fractyl recently reported Q2 results that beat analyst expectations and showed a smaller loss per share due to reduced R&D spending. » Plus sur de.investing.com

Fractyl Health presented at the Canaccord growth conference its strategy to develop one-time metabolic treatments that address weight and root causes of diabetes. Lead program Revita showed sustained weight maintenance after GLP‑1 therapy in pilot studies and is now running a 300‑patient, approval‑relevant trial with initial 6‑month data due in early Q4; a regulatory submission based on those data is planned by year‑end. Rejuva, a gene‑therapy candidate for endogenous GLP‑1 production, received IND clearance and is approaching first-in-human use. Fractyl plans to commercialize through roughly 200–400 centers of excellence rather than a broad rollout; success depends on clinical and regulatory milestones. » Plus sur de.investing.com